IBDEI0LA ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10087,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10087,1,3,0)
 ;;=3^Cranial Nerve Neopl,Malignant
 ;;^UTILITY(U,$J,358.3,10087,1,4,0)
 ;;=4^192.0
 ;;^UTILITY(U,$J,358.3,10087,2)
 ;;=Mal Neoplasm, Cranial Nerve^267290
 ;;^UTILITY(U,$J,358.3,10088,0)
 ;;=225.1^^44^561^20
 ;;^UTILITY(U,$J,358.3,10088,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10088,1,3,0)
 ;;=3^Cerebral Nerve Neopl,Benign
 ;;^UTILITY(U,$J,358.3,10088,1,4,0)
 ;;=4^225.1
 ;;^UTILITY(U,$J,358.3,10088,2)
 ;;=Benign Neoplasm Cranial Nerve^13298
 ;;^UTILITY(U,$J,358.3,10089,0)
 ;;=346.90^^44^561^47
 ;;^UTILITY(U,$J,358.3,10089,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10089,1,3,0)
 ;;=3^Headache,Migraine
 ;;^UTILITY(U,$J,358.3,10089,1,4,0)
 ;;=4^346.90
 ;;^UTILITY(U,$J,358.3,10089,2)
 ;;=Headache, Migraine^293880
 ;;^UTILITY(U,$J,358.3,10090,0)
 ;;=784.0^^44^561^46
 ;;^UTILITY(U,$J,358.3,10090,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10090,1,3,0)
 ;;=3^Headache
 ;;^UTILITY(U,$J,358.3,10090,1,4,0)
 ;;=4^784.0
 ;;^UTILITY(U,$J,358.3,10090,2)
 ;;=Headache^54133
 ;;^UTILITY(U,$J,358.3,10091,0)
 ;;=V41.0^^44^561^105
 ;;^UTILITY(U,$J,358.3,10091,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10091,1,3,0)
 ;;=3^Problems with Sight
 ;;^UTILITY(U,$J,358.3,10091,1,4,0)
 ;;=4^V41.0
 ;;^UTILITY(U,$J,358.3,10091,2)
 ;;=Problem with sight^295427
 ;;^UTILITY(U,$J,358.3,10092,0)
 ;;=348.2^^44^561^56
 ;;^UTILITY(U,$J,358.3,10092,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10092,1,3,0)
 ;;=3^Intracranial Hypertension
 ;;^UTILITY(U,$J,358.3,10092,1,4,0)
 ;;=4^348.2
 ;;^UTILITY(U,$J,358.3,10092,2)
 ;;=Intracranial Hypertension^100293
 ;;^UTILITY(U,$J,358.3,10093,0)
 ;;=378.50^^44^561^78
 ;;^UTILITY(U,$J,358.3,10093,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10093,1,3,0)
 ;;=3^Ophthalmoplegia,Unspec
 ;;^UTILITY(U,$J,358.3,10093,1,4,0)
 ;;=4^378.50
 ;;^UTILITY(U,$J,358.3,10093,2)
 ;;=Opthalmoplegia, Unspec^265442
 ;;^UTILITY(U,$J,358.3,10094,0)
 ;;=351.8^^44^561^49
 ;;^UTILITY(U,$J,358.3,10094,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10094,1,3,0)
 ;;=3^Hemifacial Spasm
 ;;^UTILITY(U,$J,358.3,10094,1,4,0)
 ;;=4^351.8
 ;;^UTILITY(U,$J,358.3,10094,2)
 ;;=Hemifacial Spasm^87589
 ;;^UTILITY(U,$J,358.3,10095,0)
 ;;=446.5^^44^561^121
 ;;^UTILITY(U,$J,358.3,10095,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10095,1,3,0)
 ;;=3^Temporal Arteritis
 ;;^UTILITY(U,$J,358.3,10095,1,4,0)
 ;;=4^446.5
 ;;^UTILITY(U,$J,358.3,10095,2)
 ;;=Giant Cell Arteritis^117658
 ;;^UTILITY(U,$J,358.3,10096,0)
 ;;=378.73^^44^561^75
 ;;^UTILITY(U,$J,358.3,10096,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10096,1,3,0)
 ;;=3^Ocular Myasthenia Gravis
 ;;^UTILITY(U,$J,358.3,10096,1,4,0)
 ;;=4^378.73
 ;;^UTILITY(U,$J,358.3,10096,2)
 ;;=Ocular Myasthenia Gravis^269274
 ;;^UTILITY(U,$J,358.3,10097,0)
 ;;=377.24^^44^561^106
 ;;^UTILITY(U,$J,358.3,10097,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10097,1,3,0)
 ;;=3^Pseudopapilledema
 ;;^UTILITY(U,$J,358.3,10097,1,4,0)
 ;;=4^377.24
 ;;^UTILITY(U,$J,358.3,10097,2)
 ;;=Pseudopapilledema^269224
 ;;^UTILITY(U,$J,358.3,10098,0)
 ;;=781.0^^44^561^3
 ;;^UTILITY(U,$J,358.3,10098,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10098,1,3,0)
 ;;=3^Abnormal Involuntary Movements
 ;;^UTILITY(U,$J,358.3,10098,1,4,0)
 ;;=4^781.0
 ;;^UTILITY(U,$J,358.3,10098,2)
 ;;=Lid Myokymia^23827
 ;;^UTILITY(U,$J,358.3,10099,0)
 ;;=088.81^^44^561^57
 ;;^UTILITY(U,$J,358.3,10099,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10099,1,3,0)
 ;;=3^Lyme Anthropoed Borne Disease
 ;;^UTILITY(U,$J,358.3,10099,1,4,0)
 ;;=4^088.81
 ;;^UTILITY(U,$J,358.3,10099,2)
 ;;=^72315
 ;;
 ;;$END ROU IBDEI0LA
